HTD1801 Monotherapy Significantly Improves Glycemic Control and Cardiometabolic Health in Type 2 Diabetes: Results From a 56-Week Phase 3 Trial
Highlight
HTD1801 monotherapy led to a robust and statistically significant reduction in HbA1c (-1.3%) compared to placebo (-0.6%) after 24 weeks in patients with inadequately controlled type 2 diabetes. Improvements in key cardiometabolic and inflammatory biomarkers were observed and sustained through 52 weeks. The safety profile was favorable, with predominantly mild to moderate gastrointestinal adverse events occurring early in treatment.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.